Ashwagandha and Thyroid Hormone Interactions

Ashwagandha's relationship with the thyroid runs through two separate biological systems, not one, and the difference matters for anyone deciding whether to take it.

Ashwagandha's place in the body's two main hormonal control systems

Any claim about ashwagandha and thyroid function has to start with the machinery it's supposedly acting on, because the herb doesn't hit a single switch. The thyroid runs on a feedback loop connecting the hypothalamus, the pituitary, and the thyroid gland itself, a chain that sets metabolic rate, energy level, and mood through the interplay of TSH, T3, and T4. Pushing on any one point in that loop shifts the whole balance, since the three hormones are constantly adjusting against each other rather than acting in isolation.

The second system is the HPA axis, the hypothalamus-pituitary-adrenal loop that governs the body's stress response and cortisol output. Cortisol that stays elevated for too long doesn't just affect mood or sleep. It quietly suppresses thyroid function. The HPA axis and the thyroid axis are functionally linked even though they're often discussed as separate systems. Ashwagandha's active compounds, the withanolides, sitoindosides, and alkaloids that give the plant its pharmacological punch, act on both axes at once, and the working theory is that this happens through central regulatory pathways rather than through the compounds binding directly to hormone receptors. That distinction sets up everything that follows.

The direct thyroid pathway: what ashwagandha appears to do to T3, T4, and TSH

The clearest finding in the literature is that ashwagandha raises circulating T3 and T4 while lowering TSH, but the effect appears differently depending on the person. It appears consistently in people who start out hypothyroid or subclinically hypothyroid, and far less consistently, sometimes not at all, in people whose thyroid function was normal to begin with.

Patients took 300 mg twice a day for eight weeks, and compared to placebo, their TSH dropped while T3 and T4 climbed. Set that against what happens in people with normal thyroid function to begin with: a 2025 narrative review by Vollmer and Brendler in Phytotherapy Research found little to no meaningful change in thyroid markers in euthyroid subjects, and calls out this asymmetry directly. Something about an already-underperforming axis makes it responsive in a way a balanced one isn't.

What's less settled is why. Drugs.com's own interaction reports, covering both levothyroxine and thyroid desiccated, state that "the mechanism of interaction is not established." That's a real gap, not a rounding error, and it should temper any claim that the science here is closed. The Vollmer and Brendler review offers the most credible working hypothesis: that ashwagandha acts on central regulatory pathways, at the level of the pituitary or hypothalamus, rather than binding thyroid hormone receptors outright. If that holds up, it means the herb is shifting where the axis's setpoint sits rather than simply pouring more hormone into circulation, a distinction that matters both for understanding the benefit and for predicting where things could go wrong.

The indirect pathway: how cortisol reduction feeds into thyroid function

The direct pathway isn't the only route in play. Ashwagandha's cortisol-lowering effect, one of the most replicated findings in the adaptogen literature, isn't a separate story from its thyroid effects. Chronic cortisol elevation suppresses the thyroid axis on its own, so anything that brings cortisol down is, by definition, a second lever acting on thyroid hormone balance.

Withanolides modulate HPA-axis activity, contributing to ashwagandha's adaptogenic and anxiolytic effects, per the Vollmer and Brendler 2025 Phytotherapy Research review. This isn't a one-off finding either. A 2025 meta-analysis found a statistically significant reduction in cortisol across pooled trials, and a 12-month observational study of KSM-66 ashwagandha, run by SF Research Institute and registered as NCT06244147, completed in October 2025 and found serum cortisol declined modestly over the study period.

Putting the two mechanisms together, the practical implication is fairly direct: someone with subclinical hypothyroidism made worse by chronic stress could see improvement in thyroid hormone readings through two reinforcing channels running at once, the direct thyroid effect and the cortisol-driven indirect one. Worth a pause here, though. The same 2025 meta-analysis that found the cortisol drop also found no significant improvement in perceived stress scores. A biomarker moving in the right direction doesn't guarantee someone feels different, and it's a reminder that trial results are hard to line up against each other given how much dose, duration, and extraction method vary from one study to the next.

The subclinical hypothyroid context behind the asymmetric effect

Everything in the two prior sections points at the same population: people with subclinical hypothyroidism are where ashwagandha's thyroid effect is most likely to actually register. That's exactly the condition where a modulatory nudge is most likely to show up as a measurable shift, rather than being absorbed by a system that's already balanced.

The Sharma, Basu, and Singh 2018 trial remains the strongest direct evidence for this. Fifty participants with subclinical hypothyroidism took 300 mg twice daily for eight weeks, and their TSH normalized while T3 and T4 rose relative to placebo. Give the same dose over the same timeframe to someone with normal thyroid function, though: the Vollmer and Brendler review found essentially nothing changes. That's not a minor detail. It suggests the effect depends on the state of the axis rather than acting as a pharmacological override that pushes hormone levels up regardless of where they started.

That state-dependence is exactly what makes the risk-benefit picture different depending on who's taking it. A mild thyroid-stimulating push is plausibly useful when the axis is underactive, is likely to do nothing when it's balanced, and turns into a liability when thyroid hormone levels are already elevated, which is precisely the population the next section turns to.

When ashwagandha's thyroid-stimulating effect becomes a clinical concern

For anyone on thyroid replacement therapy, or living with Graves' disease, the same stimulating effect that helps a subclinical hypothyroid patient can pile onto hormone levels that are already too high, and the result isn't theoretical. It appears as actual clinical symptoms.

Hayashi and colleagues described a 47-year-old bodybuilder, published in Cureus in 2024, who took ashwagandha for eight weeks and developed markedly elevated thyroid hormones, a very low TSH, and elevated thyroglobulin, a pattern consistent with a hyperthyroid state. A second Cureus report from the same year described a healthy 47-year-old who started taking ashwagandha for sleep and developed thyrotoxicosis over roughly two months, with weight loss and a low-grade fever; the thyroid markers returned to normal within weeks of stopping the supplement.

The drug interaction data lines up with these cases. Drugs.com's reports for both levothyroxine (sold as Synthroid or Levoxyl) and thyroid desiccated note that ashwagandha may raise serum T3 and T4, which could add to the effect of thyroid replacement drugs like liothyronine (Cytomel); the interaction is rated moderate, with a recommendation to monitor rather than avoid. On the flip side, for people taking antithyroid medications such as methimazole or propylthiouracil, the 2025 Phytotherapy Research review recommends checking with a healthcare provider first, since stimulating thyroid output while on a drug meant to suppress it works directly against the treatment goal.

Limits of the evidence base for interpreting the case reports

The thyroid-stimulating signal is present in two case reports and one clinical trial, but that's not enough evidence to treat it as a well-quantified thyroid risk. The Vollmer and Brendler review is upfront about this, flagging small clinical sample sizes, reliance on high animal-model doses that don't necessarily translate to humans, and a general need for research that actually tracks dose-response relationships rather than testing one fixed amount.

Set that against the 12-month KSM-66 observational study (NCT06244147, completed October 2025), which found no significant changes in thyroid function over 12 months at 600 mg/day in a euthyroid population. That's not a contradiction of the risk described above, since the study population was euthyroid, and it fits the same asymmetry pattern already established: healthy thyroid function stays largely undisturbed, while an already-stressed axis is where changes tend to appear.

The case reports themselves carry a confound that needs stating directly. Both the Hayashi case and the second Cureus thyrotoxicosis case involved products and doses that were never independently verified. Compare that to the KSM-66 study, where a known, standardized dose in a documented population produced no thyroid disruption at all, and the contrast starts to look like it's about product quality and dosing precision as much as it is about the herb itself. Drug-interaction checkers often list long strings of theoretical interactions tied to CYP450 metabolism, and most of those flags are generated by software modeling rather than observed clinical events; the 12-month safety study found no changes consistent with CYP450 disruption at 600 mg/day of KSM-66. What isn't resolved yet is how the thyroid effect scales with dose, how longer use changes the picture, and how the chemical form of the withanolides involved, glycoside versus aglycone, changes the outcome. Those questions remain open.

Withanolide type, absorption quality, and delivery of any thyroid effect

None of the mechanisms discussed so far matter if the compound never reaches the bloodstream in a meaningful amount, and that's a real possibility with ashwagandha given how products vary. Two extracts can carry identical withanolide percentages on their labels and still deliver very different amounts of active compound once ingested, which makes bioavailability a determining factor rather than a footnote.

A study in Current Therapeutic Research, run on four Shoden ashwagandha extracts with varying compositions across 16 healthy volunteers, found meaningful differences in bioavailability even when total withanolide content was held constant. Benny Antony, PhD, joint managing director of Arjuna Natural, described the finding in a September 2, 2025 press release as the first direct human evidence that withanolide type, and not just total withanolide content, shapes how well the compound is absorbed and how effective it ends up being. Withanolide glycosides specifically outperformed other forms in absorption. A label listing total withanolide percentage without specifying glycoside versus aglycone content is telling you less than it seems to.

Once absorbed, withanolides concentrate mainly in the liver and brain, where cytochrome P450 enzymes metabolize them, the same enzyme family that drives most of the theoretical drug-interaction flags mentioned earlier. Given that the 12-month KSM-66 data showed no signs of that kind of disruption at standard doses in healthy adults, the practical risk from CYP450 interaction looks smaller than the interaction-checker lists suggest. Still, the underlying point holds: an uncharacterized product with a high withanolide number on the label may deliver very little active compound, while a well-characterized, glycoside-rich extract may deliver considerably more, which is part of why the case reports built on unverified products are hard to generalize from.

Who should monitor thyroid function when using ashwagandha

None of this adds up to a case for universal caution. Two distinct biological routes, an effect size that depends heavily on starting thyroid status, and a moderate (not severe) drug-interaction profile together mean monitoring isn't something every user needs to think about, but it is clearly warranted for a few identifiable groups.

Anyone taking levothyroxine (Synthroid, Levoxyl) or liothyronine (Cytomel) falls into that group. Drugs.com's interaction reports for both levothyroxine and thyroid desiccated recommend clinical and laboratory monitoring of thyroid function, and specifically call for closer observation whenever ashwagandha is started, stopped, or the dose changes. The same caution applies to people on antithyroid drugs like methimazole or propylthiouracil, where the 2025 Phytotherapy Research review recommends talking to a healthcare provider before adding ashwagandha to the regimen, given that the herb's stimulating effect runs directly opposite to what those medications are meant to do. For people in either category, or with a diagnosed hyperthyroid condition, keeping tabs on thyroid panels alongside symptoms like heart palpitations, unexplained weight loss, or new anxiety is a sensible precaution. It's the sensible response to a mechanism that's well documented, even if its exact size and limits are still being mapped out.